ANRO

SEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · derivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,405

Underlying: Common Stock · 55,000 shares

Expires 2031-09-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 9

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,818

Underlying: Common Stock · 24,056 shares

Expires 2033-12-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 6

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 5

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,946

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 4

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 8

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,625

Underlying: Common Stock · 54,375 shares

Expires 2034-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 7

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,874

Underlying: Common Stock · 56,455 shares

Expires 2033-12-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 3

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F2 · price: This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

SEC source: 0001777760-26-000016 · wk-form4_1780085758.xml · derivative · entry 1

Miller Andrew Craig · CIK 0001777760 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2036-05-26

F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the Reporting Person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on June 27, 2026, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0002007795-26-000006 · wk-form4_1778879168.xml · nonDerivative · entry 1

Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 833,949

F1 · kind: The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.

SEC source: 0002009654-26-000004 · wk-form4_1778792252.xml · derivative · entry 1

Manji Husseini · CIK 0002009654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002008499-26-000005 · wk-form4_1778792156.xml · derivative · entry 1

York Gwill · CIK 0002008499 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002008212-26-000004 · wk-form4_1778792320.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001830326-26-000005 · wk-form4_1778792418.xml · derivative · entry 1

Sanchez Ramiro · CIK 0001830326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001670893-26-000002 · wk-form4_1778792215.xml · derivative · entry 1

Dreyfus Andrew · CIK 0001670893 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002009130-26-000002 · wk-form4_1772583322.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · shares: Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person.

SEC source: 0002007795-26-000002 · wk-form4_1772583360.xml · nonDerivative · entry 1

Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,233,949

F1 · shares: Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person.

SEC source: 0002009130-26-000001 · wk-form4_1771021115.xml · derivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-02-10

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002008707-26-000001 · wk-form4_1771021170.xml · derivative · entry 1

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,000

Underlying: Common Stock · 124,000 shares

Expires 2036-02-10

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002007795-26-000001 · wk-form4_1771021213.xml · derivative · entry 1

Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 306,000

Underlying: Common Stock · 306,000 shares

Expires 2036-02-10

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001791413-26-000001 · wk-form4_1771021048.xml · derivative · entry 1

Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,000

Underlying: Common Stock · 131,000 shares

Expires 2036-02-10

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002009654-26-000002 · wk-form4_1767735986.xml · derivative · entry 1

Manji Husseini · CIK 0002009654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,228

Underlying: Common Stock · 4,228 shares

Expires 2036-01-01

F1 · derivative.exercise_date: 1,057 shares underlying the option shall vest on each of March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F2 · balance_after: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $50,000.

SEC source: 0002008499-26-000002 · wk-form4_1767736064.xml · derivative · entry 1

York Gwill · CIK 0002008499 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,243

Underlying: Common Stock · 5,243 shares

Expires 2036-01-01

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000.

F1 · derivative.exercise_date: 1,311 shares underlying the option shall vest on March 31, 2026, 1,311 shares underlying the option shall vest on June 30, 2026, 1,310 shares underlying the option shall vest on September 30, 2026 and 1,311 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002008212-26-000002 · wk-form4_1767736023.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,189

Underlying: Common Stock · 7,189 shares

Expires 2036-01-01

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000.

F1 · derivative.exercise_date: 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001830326-26-000002 · wk-form4_1767735946.xml · derivative · entry 1

Sanchez Ramiro · CIK 0001830326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,806

Underlying: Common Stock · 3,806 shares

Expires 2036-01-01

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000.

F1 · derivative.exercise_date: 952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000081 · wk-form4_1755206542.xml · derivative · entry 2

Sanchez Ramiro · CIK 0001830326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,928

Underlying: Common Stock · 3,928 shares

Expires 2035-08-11

F4 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07.

F3 · derivative.exercise_date: 1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000081 · wk-form4_1755206542.xml · derivative · entry 1

Sanchez Ramiro · CIK 0001830326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,574

Underlying: Common Stock · 30,574 shares

Expires 2035-08-11

F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 10

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 135,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 9

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 8

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 7

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 6

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 202,329 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 5

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,329

Underlying: Common Stock · 202,329 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 4

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,833 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 3

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,833

Underlying: Common Stock · 33,833 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,962 shares

Expires 2032-09-21

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,962

Underlying: Common Stock · 44,962 shares

Expires 2032-09-21

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 10

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 76,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 9

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 8

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 7

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,000

Underlying: Common Stock · 73,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 6

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 123,645 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 5

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,645

Underlying: Common Stock · 123,645 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 4

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,008 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 3

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,008

Underlying: Common Stock · 33,008 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 2

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,481 shares

Expires 2032-08-01

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 1

Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,481

Underlying: Common Stock · 22,481 shares

Expires 2032-08-01

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.